30th Nov & 1st Dec 2016

LILLE, FRANCE

Biofit Fostering NNOVATION & TRANSFER

A 360° approach to source early stage innovations in Life Sciences

AGENDA

ORGANISED BY





IN COLLABORATION WITH

WITH THE SUPPORT OF



Alsoce BioValley

ABOUT BIOFIT 2016





50% INTERNATIONAL ACTORS **30+** COUNTRIES REPRESENTED





30+ 11 60 800 one-to-one meetings conferences high-level licensing per participant over and roundtable international opportunities (in 2015) 2 days discussions speakers

STEERING COMMITTEE

PHARMAS, BIOTECHS



Zeina ANTOUN CLINICAL RESEARCH DIRECTOR, GSK - GLAXOSMITHKLINE [FR]



Maria BOBADILLA SENIOR DIRECTOR, EXTENDING INNOVATION NETWORK, ROCHE [CH]



Adrian CARTER CORPORATE VICE PRESIDENT AND GLOBAL HEAD OF DISCOVERY RESEARCH COORDINATION, BOEHRINGER INGELHEIM [DE]



DIRECTOR OF TECHNOLOGY PLATFORMS AND INNOVATION, LFB [FR]

Sami CHTOUROU



Florence DAL DEGAN R&D INNOVATION SOURCING DIRECTOR, NOVO NORDISK [DK]



Isabelle DIEUZY-LABAYE FORMER DIRECTOR, STRATEGIC ALLIANCES, ZOETIS [FR]



Guy HELIN CEO, SYNGULON [BE]



Sarah HOLLAND HEAD OF EUROPE, EXTERNAL SCIENCE & PARTNERING, SANOFI [FR]

Stephan LENSKY CHIEF OPERATING AND CHIEF BUSINESS OFFICE, EPIMAB



BIOTHERAPEUTICS [CN] Sabrina LESAGE STRATEGIC ALLIANCES MANAGER, PFIZER [FR]



Frédéric SCAEROU DIRECTOR, SCIENTIFIC AFFAIRS ONCOLOGY, IPSEN INNOVATION [FR]

ACADEMIA, TTOs



Hervé ANSANAY OPERATIONS DIRECTOR. SATT AXLR [FR]

CHIEF OPERATING OFFICER,

MAX PLANCK INSTITUTE OF

MOLECULAR CELL BIOLOGY AND

Ivan BAINES

GENETICS [DE]









Nicolas CARBONI PRESIDENT, SATT CONECTUS ALSACE [FR]

Jean-Luc CHAGNAUD HEALTHCARE BUSINESS DEVELOPMENT MANAGER & INTELLECTUAL PROPERTY MANAGER, AQUITAINE SCIENCE TRANSFERT [FR]



Esther LANGE INDUSTRY LIAISON MANAGER, ASCENION [DE]

LIFE SCIENCES EXPERT,

SATT NORD [FR]

Matthieu FISICHELLA

ASSOCIATIONS, CLUSTERS, **INVESTORS & LAW FIRMS**



Christian POLICARD MEMBER OF THE BOARD. CHAIRMAN OF THE BUSINESS DEVELOPMENT SUB-COMMITTEE, FRANCE BIOTECH [FR]

Claude-Alain CUDENNEC



GENERAL DIRECTOR, AFSSI -FRENCH ASSOCIATION OF OUTSOURCING AND INNOVATIVE COMPANIES [FR]



Marco FIORINI

GENERAL SECRETARY, AVIESAN -FRENCH NATIONAL ALLIANCE FOR LIFE SCIENCES AND HEALTH



Barbara FREISCHEM MANAGING DIRECTOR, EBE -EUROPEAN BIOPHARMACEUTICAL ENTERPRISES [BE]



Didier FROMMWEILER GENERAL MANAGER, ALSACE BIOVALLEY [FR]



Sara NUNEZ-GARCIA SENIOR ASSOCIATE. SOFINNOVA PARTNERS [FR]



Emilie ROYERE DIRECTOR, EUROBIOMED [FR]



Cécile THEARD-JALLU PARTNER ATTORNEY, DE GAULLE FLEURANCE & ASSOCIÉS [FR]



Etienne VERVAECKE GENERAL MANAGER, EURASANTE & NHL CLUSTER [FR]

PARTNERING

48 hours to meet your future project partners and accelerate innovation



Partnering at BioFIT is powered by partneringONE*

a product of EBDGROUP

PRESENTATION SESSIONS

The early stage innovations you need

The BioFIT presentation sessions offer the opportunity to detect the most innovative and promising start-ups, R&D projects and licensing opportunities in order to foster partnerships and business development opportunities in the Life Sciences sector.



Discover the innovative R&D projects stemming from academia Licensing Opportunity Presentations*

Start-up

Slams

Discover the most

innovative start-ups

(≤ 3 years old or about

to be created)

Discover the best "ready to be licensed" technologies from TTOs and related structures

These technologies will be related to the following areas: Oncology, Neurology, Cardiology, Infectiology and Vaccines



*Organised in partnership with TechnoMarket Life Sciences, an event organised by Reseau SATT



CONFERENCE PROGRAMME



Best practices in collaborative research



Key issues in licensing and tech transfer



Funding early stage innovation

Plenary Session



MODERATOR: John Carroll EDITOR, ENDPOINTS

KEYNOTE

PETER GRUSS « Academic-/ biotech-/pharma-cooperations require new models »

PANEL DISCUSSION

Is Europe competitive enough in Life Sciences innovation?

Piyush Unalkat

HEAD OF TECHNOLOGY TRANSFER INVESTMENTS, INNOVATION & TECHNOLOGY INVESTMENTS, EUROPEAN INVESTMENT FUND

Ron Newbold

VP EXTERNAL R&D INNOVATION, PFIZER WORLDWIDE RESEARCH & DEVELOPMENT



Paul Ashley DEPUTY HEAD OF TECH TRANSFER, ISIS INNOVATION

Magnus Björsne CEO, Astrazeneca bioventurehub Jasper Bos VICE PRESIDENT HEALTHCARE, MERCK VENTURES

Nicolas Carboni PRESIDENT, SATT CONECTUS ALSACE

John Carroll EDITOR, ENDPOINTS

Sam Fazeli HEAD OF BLOOMBERG INTELLIGENCE, EMEA; SENIOR PHARMACEUTICAL ANALYST, BLOOMBERG INTELLIGENCE

Roberto Gradnik CEO, IXALTIS

Daniel Green CEO, YAQRIT

Christophe Guichard DIRECTOR, ECLOSION

SPEAKERS

Thierry Laugel MANAGING PARTNER, KURMA PARTNERS

Nicolas Marro European Patent Attorney, BEAU DE LOMÉNIE

Soren Moller Managing Partner, NOVO SEEDS

VC PARTNER, FUND+

Ron Newbold VP EXTERNAL R&D INNOVATION, PFIZER WORLDWIDE RESEARCH & DEVELOPMENT

Stefan K. Nilsson CEO, LIPIGON

Michèle Ollier PARTNER AND COFOUNDER, MEDICXI VENTURES 🛟 Katja Rosenkranz PRINCIPAL, V-BIO VENTURES

Kees de Ruig BUSINESS DEVELOPMENT MANAGER, EATRIS

Kai Simons CEO LIPOTYPE & DIRECTOR EMERITUS OF THE MAX PLANCK SOCIETY

Tzachy Tal Director BD, TECHNION

Cecile Théard-Jallu PARTNER, DE GAULLE FLEURANCE & ASSOCIÉS

Iain Thomas HEAD OF LIFE SCIENCES, CAMBRIDGE ENTERPRISE

Piyush Unalkat PRINCIPAL OF EQUITY INVESTMENTS AND HEAD OF TECHNOLOGY TRANSFER & IP INVESTMENTS,

ITI EUROPEAN INVESTMENT FUND

Einat Zisman CEO, FUTURX

DAY ONE Wednesday 30th November

	TRACK 1 Best practices in collaborative research	TRACK 2 Key issues in licensing and tech transfer	TRACK 3 Funding early stage innovation	Presentation sessions & TechnoMarket by Réseau SATT	Business Convention	
8.30 am 9.30 am	REGISTRATION AND WELCOME					
9.30 am 11.00 am			Committed to the VC business: Why and how universities are involved in new venture funds?	Licensing Opportunities and TechnoMarket £ 10 slots	One- to-one meetings	IDEA Summit
11.00 am 11.30 am	COFFEE BREAK					BREAK
11.30 am 1.00 pm	KEYNOTE PLENARY PANEL DISCU Peter Gruss SESSION Is Europe competing the sciences in Life Sciences in				tive enough	
1.00 pm 2:30 pm		LUNCH				LUNCH
2.30 pm 4.00 pm		What is the best background for an academic spin-off CEO?	How to create a European seed capital market?	Science slams ¥ 7 slots		IDEA Summit
4.00 pm 4.30 pm	POSTER EXHIBITION AND NETWORKING BREAK					BREAK
4.30 pm 5.15 pm 5.15 pm 6.00 pm		WORKSHOPS Could your innovations be protected efficiently by tools other than patents? - What about regulatory data protection, trade secret, blockchain	Part 1: Lessons learned: Dos & don't from experienced entrepreneurs Part 2: How can former successful entrepreneurs become involved and support	Licensing Opportunities and TechnoMarket £ 10 slots	ලබ් One- to-one meetings	IDEA Summit
		& smart contracts?	today's life sciences start-ups?			
7.00 pm	BIOPARTY / NETWORKING EVENING					

DAY TWO Thursday 1st December

	TRACK 1 Best practices in collaborative research	TRACK 2 Key issues in licensing and tech transfer	TRACK 3 Funding early stage innovation	Presentation sessions & TechnoMarket by Réseau SATT	Business Convention	
8.30 am 9.30 am	REGISTRATION AND WELCOME					
9.30 am 11.00 am	How can industry and investor incubator models accelerate research translation?			Licensing Opportunities and TechnoMarket £ 10 slots		SIRIC ONCO Lille Days
11.00 am 11.30 am	POSTE	er exhibition an	d networking i	BREAK		BREAK
11.30 am 1.00 pm		Are universities a short-term or long term partner for spin-offs?	How to spark the interest of VCs for Series A financing?	Start-up slams £ 7 slots	<u>5</u>	SIRIC ONCO Lille Days
1.00 pm 2.30 pm		LUNCH			One- to-one	LUNCH
2.30 pm 4.00 pm		To spin or not to spin?		Licensing Opportunities and TechnoMarket £ 10 slots	meetings	SIRIC
4.00 pm 5.00 pm	How can the deal- making process be accelerated by standard elements and framework agreements?			Start-up slams <mark>∲ 5 slots</mark>		Lille Days
5.00 pm 6.00 pm	NETWORKING BREAK / CLOSING REMARKS					

HOSTED EVENTS BY **Biofit**





Organised by AFSSI, the French Association of Outsourcing and Innovative Companies, the AFSSI conference gathers over 100 French entrepreneurs from R&D, life sciences, big company decision makers, academic research leaders, governmental regulators and investors to discuss the best relationships within the new landscape of industry R&D cooperation.

The conference will focus on the growing number of small and medium technology companies driven by the needs of biopharma companies to optimise research costs and of academia to advance research programmes to maturity.

www.afssi.fr/conference



TechnoMarket is an event created by Réseau SATT to discover innovative technologies from public research. It is a real market place for companies ready to innovate. The technologies presented will be selected by an expert committee with a call for applications stemming from French and European transfer structures.

* Activity organised in partnership with BioFIT Licensing Opportunity Presentations

INNOVATION IN CARDIOMETABOLIC DISEASES



Organised by EGID, the European Genomic Institute for Diabetes, the 4th edition of the EGID Symposium is hosted by BioFIT and organised in collaboration with IDEA Summit.

The Steering Committee and speakers – world leaders in their fields – will present the latest scientific advances in diabetes and related disorders. This year, EGID Symposium is about "Liver, Diabetes and Cardiovascular Risks".

This symposium provides an opportunity for young researchers to present their work during poster presentations and to win the «Best Poster Award» (€1,000).

www.egid.fr

Discover innovative technologies during 2 days of pitch presentations and poster exhibition dealing with **ONCOLOGY**, **INFECTIOLOGY AND VACCINES, CARDIOLOGY**, **NEUROLOGY** and schedule B-to-B appointments to meet, exchange and deepen the addressed issues.

www.technomarket.fr



ORGANISED BY

INNOVATION IN DIABETES





This 4th edition of the IDEA Summit is organised by Lund University Diabetes Center, Eurasanté and the Nutrition Health Longevity cluster, and supported by Ascenion, AstraZeneca, Novo Nordisk and Sanofi, in collaboration with BioFIT Event and EGID Symposium.

The IDEA Summit is a unique European event dedicated to collaborative research and to technology transfer in the field of diabetes.

The summit aims to be a platform for dialogue and to strengthen the links between academia and industry. At previous editions of the IDEA Summit, academia and industry enhanced their understanding of each other's strengths and driving forces. However, there is still a significant need to develop new ways of stimulating interaction and sharing knowledge and resources more effectively.

The organisers want to go even further by involving patients and creating long-term links between academia and industry.



Organised by SIRIC ONCOLIIIe, an Integrated Cancer research consortium in Lille supporting clinicians and researchers in the field of oncology, ONCOLIIIE Days feature a programme of conferences and poster presentations around oncology. The translational research consortium ONCOLIIIE is promoting a swift transfer between basic and clinical researches in the Lille area on two major issues of modern oncology: the tumor resistance to loco-regional treatments and the tumor dormancy (or resilience) after remission.

During the scientific symposium, the SIRIC ONCOLille Days, researchers will present their latest discoveries on the molecular mechanisms explaining the tumor cell resistance to treatment (MET receptors, MUC4-ErbB2 complexes, calcium canals involvement, immunosuppressive role of regulatory T cells...) or explaining cancer cell persistence after treatment (immuneevasion due to PD1-PDL1 interactions, tumor cell clonality...). Drug development strategies based on those finding will be discussed.

www.oncolille.fr

www.idea-summit-diabetes.com

ORGANISED BY









SPONSORED BY



HOSTED EVENTS PROGRAMME 🔊 Biofit







	CONTERENCE				
8.30 am	29 th Nov	29 th Nov	30 th Nov	1 st Dec	
	Registration & welcome	Registration & welcome	Registration & welcome		
9.30 am 10.00 am		Post-translational protein modifications as a novel mechanism of hepatic fibrosis			
10.20 am 10.30 am	Highlighting AFSSI Members' (life sciences R&D service providers) solid and complementary expertise	Fatty liver, lipoprotein metabolism	Pitches and posters	Pitches and posters	
10.40 am		and cardiovascular risk			
11.00 am				Poster exhibition &	
11.30 am	Break	Hepatic Steatosis	Break	networking break	
12.00 pm			BioFIT	BioFIT	
12.30 pm		Poster presentations	Plenary Session	Start-up slams	
1.00 pm	Lunch	Lunch	Lui	nch	
2.30 pm	Building sustainable relationships	Alterations in DNA methylation and type 2 diabetes	BioFIT	Pitches and posters	
3.30 pm	between industrial life sciences R&D stakeholders	Histological classification of NAFLD: limits and perspectives	Science slams		
4.00 pm	Break	Molecular mechanisms of liver fibrosis (title to be confirmed)	Poster exhibition & networking break	BioFIT	
5.00 pm		Best Paper Award		Start-up slams	
5.30 pm	Benchmarking similar European R&D provider networks	Conclusions	Pitches and posters		
6.00 pm					





8.30 am	30 th Nov	1 st Dec	30 th Nov	l⁵ Dec	
	Registration & welcome		Registration & welcome		
9.30 am 10.00 am 10.20 am				Innovative therapies against tumor resistance and dormancy \$\overline{\vee}x 5 10.20	
10.30 am 10.40 am	resistance a breaking ground for innovation?	stance a breaking Partnering	¥X3 10.20		
				Innovative tools and pre-clinical models Ψ x 1	
11.00 am	Break			Break	
12.00 pm	BioFIT Plenary Session		BioFIT Plenary Session	Innovative tools and pre-clinical models \$\vert x 4\$	
1.00 pm 2.00 pm 2.30 pm	LUI	ch	Lunch	Lunch	
2.50 pm	What are pharma's			Innovative tools and pre-clinical models 🖢 x 1 Human and social	
3.30 pm	of licensing and collaborative research in diabetes?	Partnering		sciences $\Psi x 2$ Clinical investigations	
4.00 pm		during BioFIT	Partnaring	₽x1	
4.30 pm	Break 5 minutes to persuade		Partnering during BioFIT	ONCOLILLE 2 💩 x 1 Strategic Workshop	
5.30 pm	& start-up pitches)				
6.00 pm	innovative start-ups in diabetes in 2015/2016				

REGISTER NOW FOR BIOFIT 2016

REGISTRATION FEES (excl. VAT)

Mature company (> 3 years old)	€ 1,199
TTO Research Institute Cluster Association	€ 1,019
Emerging company (≤ 3 years old) or SME (≤ 5 employees)	€ 479
Academic scientist	€ 399

EXHIBITION FEES (excl. VAT)

As an exhibitor, you will gain high visibility with the leaders in the Life Sciences field.

Equipped booths:



SPONSORSHIP OPPORTUNITIES (excl. VAT)

Discover our sponsorship opportunities and maximise your presence:



Gold Sponsor € 15,000



Silver Sponsor € 9,000



Bronze Sponsor € 6,000 There are many additional visibility opportunities, please contact us for more information.

THEY SUPPORT US



EVENT VENUE Lille Grand Palais 1 Boulevard des Cités Unies 59777 Lille - France

www.biofit-event.com

W@BIOFIT_EVENT

CONTACTS

Margaux Satola

Business Development Manager <u>msatola@eurasante.com</u> +33 (0)3 59 39 01 82

Claire Lesnik

Conference Officer clesnik@eurasante.com +33 (0)3 59 39 01 87

Lille is located at the crossroads of four major European capitals.

This location is a strategic asset, positioning Lille at the centre of the most heavily populated and richest area in Europe.

The region is the third most attractive in France in terms of real estate costs. In Europe, the city of Lille is ranked number in terms of best operating costs.

The local health sector is a key part of the regional economy:

1,000+ COMPANIES 28,500+ EMPLOYEES A €11.3 BILLION TURNOVER





INSTITUTIONAL PARTNERS

